Free Submission Public Relations &
Deutsch English


New Market Research Report: Irritable Bowel Syndrome - Pipeline Review, H1 2013

Print article Print article
2013-03-31 15:30:13 - Fast Market Research recommends "Irritable Bowel Syndrome - Pipeline Review, H1 2013" from Global Markets Direct, now available

Global Markets Direct's, 'Irritable Bowel Syndrome - Pipeline Review, H1 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Irritable Bowel Syndrome, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Irritable Bowel Syndrome. Irritable Bowel Syndrome - Pipeline Review, Half Year is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team.

Full Report Details at
- ..

Note*: Certain sections in the report may be removed or

altered based on the availability and relevance of data for the indicated disease.


* A snapshot of the global therapeutic scenario for Irritable Bowel Syndrome.
* A review of the Irritable Bowel Syndrome products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
* Coverage of products based on various stages of development ranging from discovery till registration stages.
* A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
* Coverage of the Irritable Bowel Syndrome pipeline on the basis of route of administration and molecule type.
* Key discontinued pipeline projects.
* Latest news and deals relating to the products.

Reasons to buy

* Identify and understand important and diverse types of therapeutics under development for Irritable Bowel Syndrome.
* Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
* Plan mergers and acquisitions effectively by identifying players of the most promising pipeline.
* Devise corrective measures for pipeline projects by understanding Irritable Bowel Syndrome pipeline depth and focus of Indication therapeutics.
* Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
* Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.

Partial Table of Contents:

Table of Contents
Table of Contents
List of Tables
List of Figures
Global Markets Direct Report Coverage
Irritable Bowel Syndrome Overview
Therapeutics Development
An Overview of Pipeline Products for Irritable Bowel Syndrome
Irritable Bowel Syndrome Therapeutics under Development by Companies
Irritable Bowel Syndrome Therapeutics under Investigation by Universities/Institutes
Late Stage Products
Comparative Analysis
Mid Clinical Stage Products
Comparative Analysis
Early Clinical Stage Products
Comparative Analysis
Discovery and Pre-Clinical Stage Products
Comparative Analysis
Irritable Bowel Syndrome Therapeutics - Products under Development by Companies
Irritable Bowel Syndrome Therapeutics - Products under Investigation by Universities/Institutes
Companies Involved in Irritable Bowel Syndrome Therapeutics Development
AstraZeneca PLC
Dainippon Sumitomo Pharma Co., Ltd.
Albany Molecular Research, Inc.
Astellas Pharma Inc.
Dong-A Pharmaceutical Co., Ltd.
Kureha Corporation
Ono Pharmaceutical Co., Ltd.
Menarini Group
Shire Plc
Pharmos Corporation
Lexicon Pharmaceuticals, Inc.
Yuhan Corporation
ProMetic Life Sciences Inc.
Probiomics Ltd.
Alba Therapeutics Corporation
Ironwood Pharmaceuticals, Inc.
Respiratorius AB
Tioga Pharmaceuticals, Inc.
Targacept, Inc.
Drais Pharmaceuticals, Inc.
Synergy Pharmaceuticals, Inc.
Napo Pharmaceuticals, Inc.
Ferring Pharmaceuticals, Inc.
Alfa Wassermann S.p.A
MicroDose Therapeutx, Inc.
RaQualia Pharma Inc.
Irritable Bowel Syndrome - Therapeutics Assessment
Assessment by Monotherapy Products
Assessment by Combination Products
Assessment by Route of Administration
Assessment by Molecule Type
Drug Profiles
ramosetron - Drug Profile
ibodutant - Drug Profile
crofelemer - Drug Profile
LX-1031 - Drug Profile
LIBS - Drug Profile
M-0014 - Drug Profile
linaclotide - Drug Profile
linaclotide - Drug Profile
rifaximin - Drug Profile
asimadoline - Drug Profile
asimadoline - Drug Profile
M-0012 - Drug Profile
MDT-006 - Drug Profile
AST-120 - Drug Profile
dextofisopam - Drug Profile
plecanatide - Drug Profile
dexloxiglumide - Drug Profile
solabegron hydrochloride - Drug Profile
larazotide acetate - Drug Profile
TC-6499 - Drug Profile
ALB-137391(a) - Drug Profile
RQ-00202730 - Drug Profile
elobixibat - Drug Profile
PBI-1737 - Drug Profile
eluxadoline - Drug Profile
RQ-00310941 - Drug Profile
DA-6886 - Drug Profile
RDX-5791 - Drug Profile
ONO-2952 - Drug Profile
LX-1033 - Drug Profile
ASP-7147 - Drug Profile
YH-12852 - Drug Profile
(Mosapride + Bacillus subtilis + Streptococcas feacium) - Drug Profile
DSP-6952 - Drug Profile
mexiletine hydrochloride - Drug Profile
Irritable Bowel Syndrome Therapeutics - Drug Profile Updates
Irritable Bowel Syndrome Therapeutics - Discontinued Products
Irritable Bowel Syndrome Therapeutics - Dormant Products
Irritable Bowel Syndrome - Product Development Milestones
Featured News & Press Releases
Secondary Research
Primary Research
Expert Panel Validation

Full Table of Contents is available at:

About Global Markets Direct

Global Markets Direct is a leading provider of global business intelligence and market analysis. It publishes a range of high quality company and market reports created by its large research and analysis capability and drawing from its extensive unique databases of industry-specific information. View more research from Global Markets Direct at

About Fast Market Research

Fast Market Research is an online aggregator and distributor of market research and business information. We represent the world's top research publishers and analysts and provide quick and easy access to the best competitive intelligence available.

For more information about these or related research reports, please visit our website at or call us at 1.800.844.8156.

Bill Thompson
Phone: 18008448156

Disclaimer: If you have any questions regarding information in these press releases please contact the company added in the press release. Please do not contact pr-inside. We will not be able to assist you. PR-inside disclaims contents contained in this release.
Latest News
Read the Latest News


Terms & Conditions | Privacy | About us | Contact